Clinical reports have demonstrated that the lower response to CLOP therapy in CAD patients with DM is attributed to the low exposure of CLOP-AM, which may be associated with the altered activities of some hepatic enzymes in DM status (Yang and Liu, 2020), such CYP2C19 and CES1. Here, CYP2C19 is linked to diabetes mellitus.